doxycycline and glp 1 Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, Emerging Strategies Abstract TH929: GLP-1 Receptor Gastrointestinal Health Size:(California Only)

doxycycline and glp 1 Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, Emerging Strategies Abstract TH929: GLP-1 Receptor Gastrointestinal Health Size:(California Only)

Abstract TH929: GLP-1 Receptor Agonist Medication Use Persistence in the All of Us Research Program | Circulation

Chronic Complication Mechanisms: Sustained hyperglycemia damages small vessels (microvascular disease) via multiple mechanisms including AGE accumulation, protein kinase C activation, and hexosamine pathway flux

Gastrointestinal Health

Size:(California Only)

Methodologically akin to a retrospective cohort analysis, our study differs in that it emulates a target trial by prespecifying the protocol, aligning index date, and using propensity score matching to emulate randomization, thereby reducing immortal-time bias, improving transparency, and aligning real-world evidence generation with clinical trial standards